APS.TO - Aptose Biosciences Inc.
| Previous Close | 3.45 |
| Open | 3.44 |
| Bid | 3.43 x 0 |
| Ask | 3.55 x 0 |
| Day's Range | 3.40 - 3.50 |
| 52 Week Range | 1.64 - 5.97 |
| Volume | 19,504 |
| Avg. Volume | 35,107 |
| Market Cap | 120.438M |
| Beta | 0.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.82 |
| Earnings Date | Nov 12, 2018 - Nov 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.04 |
- GlobeNewswire•18 hours ago
Aptose to Present at Upcoming Investor Conferences in October 2018
SAN DIEGO, Calif. and TORONTO, Sept. 25, 2018-- Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced ...
- ACCESSWIRE•16 days ago
Today's Research Reports on Aralez Pharmaceuticals, OrganiGram Holdings, Oncolytics Biotech and Aptose Biosciences
NEW YORK, NY / ACCESSWIRE / September 10, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
- GlobeNewswire•28 days ago
Aptose to Present at Upcoming Investor Conferences in September 2018
SAN DIEGO and TORONTO, Aug. 29, 2018-- Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that ...
- GlobeNewswire•last month
Aptose Announces Appointment of Carol Ashe to Board of Directors
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Ms. Carol Ashe to the Board of Directors effective immediately. Aptose’s Board of Directors now includes seven members with extensive experience across diverse disciplines in biotechnology, pharmaceutical development and financial experience. Ms. Ashe is an accomplished executive leader with more than 25 years of experience in corporate, legal, business development and venture capital in the pharmaceutical and biotech industries.
- ACCESSWIRE•2 months ago
Today's Research Reports on Emblem, OrganiGram Holdings, Oncolytics Biotech and Aptose Biosciences
NEW YORK, NY / ACCESSWIRE / August 10, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
- GlobeNewswire•2 months ago
Aptose Reports Results for the Second Quarter Ended June 30, 2018
SAN DIEGO and TORONTO, Aug. 07, 2018-- Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced financial ...
- Simply Wall St.•2 months ago
Breaking Down Aptose Biosciences Inc’s (TSE:APS) Ownership Structure
In this article, I’m going to take a look at Aptose Biosciences Inc’s (TSE:APS) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
- Baystreet•2 months ago
Stocks in play: Aptose Biosciences Inc
Announced that William G. Rice, Chairman, Ph.D., President and Chief Executive Officer, and Gregory ...
- GlobeNewswire•2 months ago
Aptose Biosciences to Present at Canaccord Genuity 38th Annual Growth Conference
SAN DIEGO and TORONTO, Aug. 02, 2018-- Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that ...
- GlobeNewswire•2 months ago
Aptose to Present at the 2018 Global Congress on Oncology and Cancer
SAN DIEGO and TORONTO, July 31, 2018-- Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that ...
- Zacks•2 months ago
New Strong Sell Stocks for July 27th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
- GlobeNewswire•2 months ago
Aptose To Release Second Quarter Ended June 30, 2018 Financial Results and Hold Conference Call on August 7, 2018
SAN DIEGO and TORONTO, July 24, 2018-- Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, will release its financial ...
- Zacks•3 months ago
Why Aptose Biosciences (APTO) Could Be Positioned for a Slump
Aptose Biosciences (APTO) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
- ACCESSWIRE•3 months ago
Today's Research Reports on Emblem, OrganiGram, Oncolytics Biotech and Aptose Biosciences
NEW YORK, NY / ACCESSWIRE / July 11, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
- GlobeNewswire•3 months ago
Aptose Biosciences and CrystalGenomics Announce Issuance of Japanese Patent for CG-806
SAN DIEGO, TORONTO, and SEOUL, July 10, 2018-- Aptose Biosciences Inc., today announced that the Japan Patent Office has issued Japanese Patent No. 6325573 for CG-806. The granted patent claims various ...
- GlobeNewswire•3 months ago
Aptose Biosciences to Participate at the Oppenheimer & Co. Inc. Boston Oncology Insight Summit and 1x1 Day
SAN DIEGO and TORONTO, July 09, 2018-- Aptose Biosciences Inc. today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer and Gregory Chow, Senior Vice President and Chief ...
- GlobeNewswire•3 months ago
FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers
Aptose Biosciences Inc. (APTO) (APS.TO) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that it has lifted the clinical hold on APTO-253, Aptose’s investigational drug for hematologic cancers. Up to fifteen clinical centers are expected to participate in the Phase 1b trial, and the screening and dosing will resume as soon as practicable for patients with relapsed or refractory AML or with high risk myelodysplastic syndromes (MDS).
- Simply Wall St.•3 months ago
Aptose Biosciences Inc’s (TSE:APS) Profit Outlook
Aptose Biosciences Inc’s (TSX:APS): Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company’s loss has recently broadenedRead More...
- Baystreet•4 months ago
Crown Point at 52-Week High on Buying Apco
Crown Point Energy Inc. (V.CWV) hit a new 52-week high of 70 cents Friday. Crown Point has closed its ...
- ACCESSWIRE•4 months ago
Today's Research Reports on Aptose Biosciences, Fennec Pharmaceuticals, Valeant Pharmaceuticals and BELLUS Health
NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...
- Baystreet•4 months ago
Stocks in play: Aptose Biosciences Inc.
Has entered into a Common Share Purchase Agreement of up to $20 Million U.S. with Aspire Capital Fund, ...
